Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05657496 · ClinicalTrials.gov registry record · Phase 1
Biological Response to Platelet-rich Plasma and Corticosteroid Injections
A Phase 1 study, sponsored by University of Missouri-Columbia.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT05657496 is a Phase 1 study that was terminated before completion, run by University of Missouri-Columbia. The registered enrollment target is 23 participants.
The verdict
NCT05657496, a Phase 1 study, was terminated before completion, sponsored by University of Missouri-Columbia.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The goal is to determine how two different injections, corticosteroid and platelet-rich plasma, are used to treat patients with knee osteoarthritis may affect a patient's pain and function. Secondarily, the investigators are also interested in knowing how the two types of injections that will be given may affect what happens in the joint cartilage. The participants will receive one of the two injection types at the initial visit. There will be surveys to complete (around 10 questions) about the participants' knee and overall function. The investigators will ask these same questions on seven separate occasions. In addition, the investigators will ask the participants to provide blood and urine samples at our clinic before the first knee injection and before any other injection that is needed over the course of the study. During the injections, synovial fluid will be aspirated from the participants' knee at the initial visit and the one month visit. If the participants decide to go to surgery to help relieve the pain from osteoarthritis at any point during the study, the investigators will collect the material from the participants' knee that would be normally discarded as medical waste. Previous studies have indicated that concentrations of inflammatory and degradative biomarkers in patient serum, urine, and synovial fluid may provide insight into OA pathophysiology. To our knowledge, no study has been performed to assess the impact of intra-articular PRP injection upon fluid concentrations of a comprehensive panel of proposed OA-related biomarkers. In this study, the investigators will evaluate the impact of intra-articular PRP injection upon markers of cartilage matrix turnover, inflammatory mediators, degradative enzymes, inhibitors of degradative enzymes, and markers of bone metabolism in serum, urine, and synovial fluid of knee OA patients.
Interventions
- DRUG Triamcinolone Acetonide 40 mg/ml Inj, Susp
- BIOLOGICAL Platelet-rich plasma Inj
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2022-12-28 |
| Est. Completion | 2025-06-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05657496
The ClinicalTrials.gov registry entry for NCT05657496 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Triamcinolone Acetonide 40 mg/ml Inj, Susp is the first listed.
NCT05657496 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05657496 about?
NCT05657496 is a clinical study titled "Biological Response to Platelet-rich Plasma and Corticosteroid Injections". The goal is to determine how two different injections, corticosteroid and platelet-rich plasma, are used to treat patients with knee osteoarthritis may affect a patient's pain and function. Secondarily, the investigators are also interested in knowing how the two types of injections that will be giv...
What is the current status of trial NCT05657496?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2022-12-28. Estimated completion is 2025-06-18.
What interventions are being tested in trial NCT05657496?
The interventions under investigation include: Triamcinolone Acetonide 40 mg/ml Inj, Susp (DRUG), Platelet-rich plasma Inj (BIOLOGICAL).
Who is sponsoring clinical trial NCT05657496?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.